Encinitas, California--(Newsfile Corp. - April 11, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has received grant funding from the Choroideremia Research Foundation (CRF) in support of validating functional vision assessments for patients with profound blindness. Functional vision assessments are task-oriented challenges designed to mimic real-world environments. Importantly, functional vision assessments have served... Read More

Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor conferences. Kiora will present at The 23 rd Annual Needham Virtual Healthcare Conference on April 11 th , at 10:15 am EDT. The Company will also present at The Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference, on April... Read More

Encinitas, California--(Newsfile Corp. - March 28, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, WA, May 5-9, 2024. The additional data includes quantitative evaluation of the functional MRI measures. Qualitative... Read More

Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026 Encinitas, California--(Newsfile Corp. - March 25, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its 2023 financial results and provided an update on its retinal disease development pipeline. The... Read More

Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced the publication of results from a Phase 1 double-masked study of KIO-101, a potent, non-steroidal anti-inflammatory agent. KIO-101 contains the same active molecule as KIO-104, which belongs to a family of potent anti-inflammatory agents, The study showed that a 12-day treatment of... Read More

$15 million in upfront financing with the potential to receive up to an additional approximately $30 million in potential warrant exercise proceeds for an aggregate of up to approximately $45 million in total gross proceeds Encinitas, California--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company"), a clinical-stage biopharmaceutical company focused on developing... Read More

Kiora to webcast investor conference call at 5:30 pm today; details below Encinitas, California and Clermont-Ferrand, France--(Newsfile Corp. - January 31, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage biotech company developing treatments for orphan retinal diseases, today announced that it has entered a strategic development and commercialization agreement with Théa Open Innovation (TOI), a sister... Read More

Encinitas, California--(Newsfile Corp. - November 9, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced its third quarter 2023 financial results and is providing an update on its plans to advance clinical development of KIO-301 for other inherited retinal diseases. On November 4, 2023, Kiora reported results from the ABACUS-1 study, a Phase 1b first-in-human clinical trial of the... Read More

Topline Phase I/II First-in-Human Results Presented at AAO 2023 Significant improvement in visual field, in concordance with trended improvements in visual acuity and functional vision Functional MRI demonstrates increased brain activity in visual cortex Novel small molecule photoswitch is safe and tolerable Company presentation available on IR website ( ir.kiorapharma.com ) Encinitas, California--(Newsfile Corp. - November... Read More

Encinitas, California--(Newsfile Corp. - October 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentation from the Lytham Partners Fall 2023 Investor Conference taking place on Tuesday October 17, 2023. As part of the presentation, Melisa Tosca, CPA, Kiora's Executive Vice President of Finance, will provide an overview of the Company's business and clinical development... Read More

Encinitas, California--(Newsfile Corp. - October 3, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has received Investigational New Drug Application approval in Australia to enroll up to six additional patients in the ABACUS study of KIO-301 . ABACUS was initially designed to evaluate patients with Retinitis Pigmentosa (RP). Based on encouraging findings previously shared, Kiora sought this approval to evaluate additional... Read More

Encinitas, California--(Newsfile Corp. - September 21, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced that its board of directors has appointed Praveen Tyle, PhD, who currently serves as a director, as its new Chairman. Dr. Tyle succeeds current Chairman Paul Chaney who is retiring after serving 17 years on the board. "We look forward to Dr. Tyle's leadership as Chairman, where he'll continue to bring valuable... Read More

Encinitas, California--(Newsfile Corp. - September 18, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced the completion of the final patient's last endpoint evaluation from the ABACUS study of KIO-301. KIO-301 is A molecular photoswitch being evaluated in a Phase 1B clinical trial for vision restoration in late-stage Retinitis Pigmentosa (RP). Topline study results will be reported November 4 at the upcoming... Read More

Encinitas, California--(Newsfile Corp. - September 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from the ABACUS study of KIO-301 in patients with late-stage retinitis pigmentosa will be presented at the American Academy of Ophthalmology (AAO 2023) conference on November 4, 2023. The late-breaking abstract has been accepted for presentation at the retinal... Read More

Encinitas, California--(Newsfile Corp. - September 1, 2023) - Kiora Pharmaceuticals, In c. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that the Company's Special Meeting of Stockholders (the "Special Meeting") held on August 31, 2023 at 9:00 a.m. Pacific Time was convened and adjourned, without any business being conducted, due to lack of the required quorum. A quorum consists of one third of the voting power of the... Read More

Live Event to be Held Thursday, August 31, at 7:30 pm Eastern Time Encinitas, California--(Newsfile Corp. - August 29, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites you to participate in a webinar highlighting the progress of molecular photoswitches in retinitis pigmentosa and the future development plans in additional inherited retinal diseases such as choroideremia. The webinar is being hosted by the Choroideremia... Read More

Encinitas, California--(Newsfile Corp. - August 23, 2023) - Kiora Pharmaceuticals, Inc . (NASDAQ: KPRX) ("Kiora" or the "Company") today announced it has been granted U.S. (Patent # 11,730,716) and European Patents covering local ocular delivery of the KIO-100 family of non-steroidal, anti-inflammatory small molecules. This intellectual property (IP) further protects Kiora's pipeline by covering multiple small molecule... Read More

Encinitas, California--(Newsfile Corp. - August 16, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) welcomes investors to watch the Company's online presentation from the H.C. Wainwright 3 rd Annual Ophthalmology Virtual Conference. As part of the talk, Kiora President & CEO Brian Strem, Ph.D., details the Company's sharpened focus on rare retinal diseases. This includes continued development of KIO-301 for the treatment of... Read More

Positive Preliminary Data Reported in Q2 Demonstrated Clear Clinical Proof-of-Concept of KIO-301 in the Ongoing Phase 1 Study in Retinitis Pigmentosa Supporting Advancement to Planned Higher Doses with Full Topline Results Expected in Q4 2023 Data Supports Hypothesized Mechanism of Action of KIO-301, Opening Potential to Treat Other Orphan Retinal Disease Programs, Including Choroideremia and Stargardt's Disease Management... Read More

Encinitas, California--(Newsfile Corp. - August 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), a clinical-stage ophthalmic pharmaceutical company developing novel therapeutics for patients with high unmet needs, and the Choroideremia Research Foundation (CRF), the largest organization in the world focused on the search... Read More

Encinitas, California--(Newsfile Corp. - August 1, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) has appointed Carmine Stengone as an independent member to the Company's board of directors. Stengone currently serves as the President and CEO of Pipeline Therapeutics, a company developing precision medicines to treat neurodegenerative diseases. With the insights gained throughout his career and most recently from his time... Read More

Encinitas, California--(Newsfile Corp. - July 5, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its wholly owned subsidiaries have received, in aggregate, $1.2 million related to research tax incentives from the Austrian and Australian governments for research expenditures performed in 2021 and 2022. The funds were received as part of government incentive programs to conduct critical research and development... Read More

Amendment eliminates $4.75M in near-term milestones Kiora would have owed to Sentrx Sentrx gains access to Kiora's recently issued patents covering the combination of KIO-201 and antibiotics for veterinary use Kiora will receive a royalty on net sales of products covered by licensed patents Encinitas, California--(Newsfile Corp. - June 15, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora") and Sentrx Animal Care... Read More

Encinitas, California--(Newsfile Corp. - June 14, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its President & CEO, Brian Strem, Ph.D., will participate in two upcoming investor conferences. The Healthcare Virtual Conference hosted by Maxim Group June 20, 2023 from 10:00 to 10:30 am EDT Dr. Strem will provide a brief overview followed by a 20-to-25-minute live Q&A Investors are invited to view the... Read More

Encinitas, California--(Newsfile Corp. - June 6, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.3 million, which includes full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering... Read More

Encinitas, California--(Newsfile Corp. - June 2, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.5 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of (i) 1,447,628 shares of common stock, (ii) 3,908 shares of Series F Convertible... Read More

Encinitas, California--(Newsfile Corp. - May 9, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA). CEO Commentary "This has... Read More

Encinitas, California--(Newsfile Corp. - May 1, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) announced today an encore presentation on KIO-301 neuroimaging results at The American Society of Neuroradiology 2023 Meeting in Chicago. The late-breaking abstract presentation titled "Functional Vision Reanimation in Retinitis Pigmentosa using an Intravitreal 'Photoswitch' Molecule (KIO-301): Functional MRI Protocol and Preliminary... Read More

Encinitas, California--(Newsfile Corp. - April 27, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented preliminary results from an ongoing clinical trial showing its investigational drug, KIO-301, has the potential to restore light perception in patients who are blind or living with ultra-low vision due to retinitis... Read More

In a second presentation, Kiora shared additional positive results for its KIO-100 platform in the treatment of autoimmune uveitis. Encinitas, California--(Newsfile Corp. - April 26, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) presented results of a Phase 2 clinical trial for KIO-201 treating patients with Persistent Corneal Epithelial Defects (PCEDs) at the Association for Research in Vision and Ophthalmology (ARVO)... Read More

Encinitas, California--(Newsfile Corp. - April 21, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) has appointed Mark Pennesi, M.D., Ph.D., the Kenneth C. Swan Endowed Professor in Ophthalmology and Molecular and Medical Genetics and the Chief of the Paul H. Casey Ophthalmic Genetics Division at the Casey Eye Institute at Oregon Health & Science University, to their Scientific Advisory Board. As a member of the Scientific... Read More

Encinitas, California--(Newsfile Corp. - April 17, 2023) - Kiora Pharmaceuticals (NASDAQ: KPRX) enrolled the first patient in its Phase 2 trial of KIO-101 in the treatment of the Ocular Presentations of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This clinical trial is a phase 2, multi-center, controlled, randomized, double-masked study targeting enrollment of up to 120 patients. Participants will receive one... Read More

Encinitas, California--(Newsfile Corp. - March 30, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced its late-breaking abstract detailing functional Magnetic Resonance Imaging (fMRI) results from the ABACUS Phase 1b study of KIO-301 in patients with retinitis pigmentosa was accepted for presentation on May 1, 2023, at The American Society of Neuroradiology 2023 (ASNR23) Annual Meeting.... Read More

Encinitas, California--(Newsfile Corp. - March 23, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is providing a business update and reporting financial results for the year ended December 31, 2022. CEO Commentary "In 2022, we advanced our pipeline of three differentiated assets across... Read More

Encinitas, California--(Newsfile Corp. - March 10, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced three abstract acceptances for oral and poster presentation at the 2023 Association for Research in Vision and Ophthalmology (ARVO) meeting in New Orleans, La., April 23-27, 2023. Further results from each of these three studies will be reported at the conference. A presentation... Read More

Encinitas, California--(Newsfile Corp. - February 7, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced it has received investigational new drug application approval for a Phase 2 study of KIO-101 for the treatment of the Ocular Presentation of Rheumatoid Arthritis and other autoimmune diseases (OPRA+). This study will enroll approximately 120 patients in a multi-center,... Read More

Encinitas, California--(Newsfile Corp. - February 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced that it has entered into a common stock purchase agreement for a committed equity financing (the "Purchase Agreement") with Lincoln Park Capital Fund, LLC ("LPC"), a long-standing investor in the Company. Under the Purchase Agreement and subject to certain terms and conditions... Read More

Kiora is advancing a pipeline of therapeutics for rare and underserved ophthalmic diseases Anticipates reporting results in 1H 2023 from two clinical studies, one in patients with Retinitis Pigmentosa and another in patients with persistent corneal epithelial defects Expects to initiate Phase 2 trial in autoimmune disease patients experiencing ocular surface disease Encinitas, California--(Newsfile Corp. - January 9, 2023) -... Read More

Encinitas, California--(Newsfile Corp. - January 3, 2023) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") today announced enrollment has been completed in its clinical study evaluating KIO-201 in patients with Persistent Corneal Epithelial Defects ("PCED"), a rare ocular condition characterized by non-healing wounds on the surface of the eye. Results from the study are expected to be reported at an... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today the dosing of the first patient in a first-in-human open-label clinical trial for KIO-301, intended to restore vision loss in patients with Retinitis Pigmentosa (RP). RP is a rare, inherited genetic eye disease resulting in degeneration of the retinal photoreceptors (rods and cones) and often significant loss of functional vision. "We are... Read More

Retinitis pigmentosa (RP) is a cluster of genetic eye diseases that damage the retina, the light-sensitive layer of the eye. It typically affects people in their teens or 20s, although some variations initiate in children as young as 8. There is currently no cure for the disease, and it inevitably leads to total blindness. Stonegate Healthcare recently hosted an event focusing on the disease. “ Battling Blindness in... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that results from a Phase 1 study of KIO-100 (formerly PP-001) demonstrate its potential as a treatment for non-infectious uveitis, an ophthalmic inflammatory disease. The results were published today in a paper titled " A new small molecule DHODH-inhibitor [KIO-100 (PP-001)] targeting activated T cells for intraocular treatment of uveitis - a... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced today that it has received a Bid Price Compliance Letter from The Nasdaq Stock Market LLC ("Nasdaq") on October 12, 2022 informing Kiora that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Kiora was previously notified by Nasdaq on... Read More

Stonegate Capital Partners will host a virtual investor event with ophthalmology experts to discuss Retinitis Pigmentosa (RP) and the pipeline of products in development. Participants will include Christine Kay, M.D., Vitreoretinal surgeon and IRD specialist at Vitreoretinal Associates, Eric Daniels, M.D., CDO of Kiora Pharmaceuticals (NASDAQ: KPRX) and Ben Shaberman, Ph.D., from the Foundation Fighting Blindness. The 30... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company's common stock. Following the annual stockholder meeting, the board of directors approved a reverse stock split of one share of common stock for every 40 shares of common stock. On The NASDAQ Capital Market, trading on a split-adjusted basis is expected to begin on Tuesday,... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting and accounting functions as well as play a role in the company's capital markets strategy and planning. "Melissa brings to our company more than 15 years of financial and operational experience in both... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended June 30, 2022. "In the first half, we continued to advance three core programs toward their next phase of clinical development," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "With the recent financing, we are now in a position to continue advancing these... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has been granted a U.S. patent covering hydrogel-based sustained release platforms, inclusive of KIO-201, which enable controlled release of antibiotics for the treatment of ocular diseases. The intellectual property, US Patent No. 11,376,214, relates to non-blurring, antibiotic-containing hydrogel compositions that have an extended contact time on the eye... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.0 million, which includes full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses. The offering was comprised of (i) 23,695,697... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.2 million prior to deducting underwriting discounts and commissions and offering expenses. The offering is comprised of (i) 19,770,172 shares of common stock, (ii) 1,280 shares of Series E convertible preferred stock, (iii) 26,170,172 Class A Warrants... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Persistent Corneal Epithelial Defect (PCED), a rare ocular surface condition characterized by non-healing wounds on the eye surface. "We believe KIO-201 has the potential to address a rare ophthalmic condition in patients who have... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301, which is intended to restore lost vision in patients with Retinitis Pigmentosa, a rare, inherited genetic eye disease that causes severe loss of functional vision due to degeneration of the retinal photoreceptors (rods and cones). The ABACUS study is a Phase 1b open label, single... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced that on May 25, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it was not in compliance with requirements of Nasdaq Listing Rule 5250(c)(1) as a result of not having timely filed its Quarterly Report on Form 10-Q for the fiscal quarter ended March... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that the full results of the KIO-101 Phase 1b clinical trial are being presented at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting on April 25, 2022. The results of the vehicle-controlled, randomized clinical trial in patients with ocular surface inflammation demonstrated safety and tolerability of KIO-101 as well... Read More

Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today reported its financial results for the quarter and year ended December 31, 2021 and provided an update on recent corporate and operational activities. "We are making significant progress advancing our pipeline of treatments for ocular disease," said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. "KIO-301 was recently granted... Read More

To Participate in Ophthalmology Roundtable March 28, 10:00-11:00 AM ET To Provide On-Demand Corporate Presentation Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") has been invited to present at Maxim's 2022 Virtual Growth Conference March 28th - 30th. Company President and CEO, Brian M. Strem, Ph.D., will participate in a live ophthalmology roundtable discussion as well as provide an on-demand investor... Read More